Tıp Fakültesi / Faculty of Medicine
Permanent URI for this collectionhttps://hdl.handle.net/11727/1403
Browse
39 results
Search Results
Item Safety and Palliative Efficacy of Single-Dose 8-Gy Reirradiation for Painful Local Failure in Patients with Stage IV Non-Small Cell Lung Cancer Previously Treated with Radical Chemoradiation Therapy(2015) Topkan, Erkan; Yildirim, Berna Akkus; Guler, Ozan Cem; Parlak, Cem; Pehlivan, Berrin; Selek, Ugur; 0000-0001-8120-7123; 0000-0001-6170-0383; 0000-0001-6661-4185; 0000-0001-6908-3412; 0000-0001-8087-3140; 25752391; AAG-2213-2021; B-3671-2014; V-5717-2017; AAC-5654-2020; O-5474-2014Purpose: To investigate the safety and efficacy of single-dose 8-Gy palliative chest reirradiation (CRI) in metastatic non-small cell lung cancer (M-NSCLC) patients with painful thoracic failures (TF) within the previous radiation portal. Patients and Methods: We retrospectively analyzed the clinical data of 78 M-NSCLC patients who received single-dose 8-Gy CRI for painful TF after concurrent chemoradiation therapy to a total radiation dose of 52 to 66 Gy between 2007 and 2012. Primary endpoints included significant pain relief (SPR) defined as a >= 2 point decrement in the Visual Analogue Scale for Pain inventory (VAS-P), time to pain relief, and duration of pain control. Secondary objectives were survival and prognostic factors. Results: Treatment was well tolerated, with only 5.1% grade 3 pneumonitis and 1.3% grade 2 esophagitis. Pre-CRI median and post-CRI minimum VAS-P were 7 and 3 (P < .001), respectively. SPR was noted in 67 (85.9%) patients, and only 3 (3.9%) scored progressive pain. Median time to lowest VAS-P and duration of pain control were 27 days and 6.1 months, respectively. Median overall survival (OS) was 7.7 months, and the 1-year OS rate was 26.5%. On multivariate analyses, lower Eastern Cooperative Oncology group score (1-2; P < .001), absence of anemia (P = .001), and fewer metastatic sites (1-2; P < .001) were found to be associated with longer OS. Conclusions: Single-dose 8-Gy CRI provides safe, effective, and durable pain palliation for TF in radically irradiated M-NSCLC patients. Because of its convenience, lower cost, and higher comfort, the present protocol can be considered an appropriate option for patients with limited life spans. (C) 2015 Elsevier Inc.Item Prevention of Radiation-Induced Retinopathy with Amifostine in Wistar Albino Rats(2015) Yildirim, Berna Akkus; Cetin, Eren; Topkan, Erkan; Ozyigit, Gokhan; Cengiz, Mustafa; Surucu, Selcuk; Usubutun, Alp; Akyol, Fadil; 0000-0001-6661-4185; 25768249; V-5717-2017Item Untitled Reply(2015) Yildirim, Berna Akkus; Topkan, Erkan; 0000-0001-8120-7123; 0000-0001-6661-4185; 26502011; AAG-2213-2021; V-5717-2017Item Prognosis of Stage III NSCLC Patients Presenting with Isolated Brain Failure after Definitive Concurrent Chemoradiotherapy(2015) Topkan, Erkan; Yildirim, Berna Akkus; Guler, Ozanc; Ozdemir, Yurday; 0000-0001-8120-7123; 0000-0002-2218-2074; 0000-0001-6661-4185; AAG-2213-2021; AAG-5629-2021; V-5717-2017Item Elective Nodal Irradiation Does Not Alter Isolated Nodal Failure and Survival Outcomes in Stage III NSCLC Patients Undergoing Chemoradiotherapy(2015) Topkan, Erkan; Yildirim, Berna Akkus; Guler, Ozanc; Ozdemir, Yurday; 0000-0002-2218-2074; 0000-0001-8120-7123; 0000-0001-6661-4185; AAG-5629-2021; AAG-2213-2021; V-5717-2017Item Survival Analysis of 51 Leptomeningeal Metastatic Non Small Cell Lung Cancer Patients Treated with Whole Brain Radiotherapy(2015) Topkan, Erkan; Yildirim, Berna Akkus; Guler, Ozan C.; Ozdemir, Yurday; 0000-0001-6908-3412; 0000-0001-8120-7123; 0000-0001-6661-4185; 0000-0002-2218-2074; AAC-5654-2020; AAG-2213-2021; V-5717-2017; AAG-5629-2021Item Weight Loss before Radical Chemoradiotherapy Is Associated with Poorer Survival Outcomes in Overweight Locally Advanced NSCLC Patients(2015) Topkan, Erkan; Yildirim, Berna Akkus; Ozdemir, Yurday; Guler, Ozan C.; Ozyilkan, Ozgur; 0000-0001-6661-4185; 0000-0002-2218-2074; 0000-0001-8825-4918; 0000-0001-8120-7123; 0000-0001-6908-3412; V-5717-2017; AAG-5629-2021; AAD-2817-2021; AAG-2213-2021; AAC-5654-2020Item Effective Resolution of Lung Cancer Related Tracheal and/or Bronchial Obstruction with External Beam Radiotherapy(2015) Topkan, Erkan; Yildirim, Berna Akkus; Ozdemir, Yurday; Guler, Ozan C.; Kose, Fatih; 0000-0001-6908-3412; 0000-0001-8120-7123; 0000-0002-2218-2074; 0000-0001-6661-4185; AAC-5654-2020; AAG-2213-2021; AAG-5629-2021; V-5717-2017Item Factors Associated with Brain Metastasis Development in Radically Treated Stage IIIB Non-Small Cell Lung Cancer Patients(2015) Topkan, Erkan; Yildirim, Berna Akkus; Guler, Ozan C.; Ozdemir, Yurday; 0000-0001-6908-3412; 0000-0001-6661-4185; 0000-0001-8120-7123; 0000-0002-2218-2074; AAC-5654-2020; V-5717-2017; AAG-2213-2021; AAG-5629-2021Item Restaging of Cervical Cancer Patients Treated with Adjuvant Radiotherapy According to FIGO 2018 and Suggestions for the Next Staging: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-004)(2022) Alanyali, Senem; Balci, Beril; Esen, Caglayan Selenge Beduk; Gultekin, Melis; Yildirim, Berna Akkus; Ozkurt, Selnur; Ergen, Sefika Arzu; Gursel, Sukriye Bilge; Cetin, Ilknur Alsan; Sert, Fatma; Sari, Sezin Yuce; Ibis, Kamuran; Onal, Cem; Sahinler, Ismet; Yildiz, Ferah; Ozsaran, ZeynepOBJECTIVE The objective of this study was to compare Federation of Gynecology and Obstetrics (FIGO) 2009 and 2018 staging systems in patients with uterine cervical cancer. METHODS Medical records of 571 patients who were treated with adjuvant radiotherapy or radiochemotherapy between 2001 and 2018 were retrospectively reviewed. Differences in overall survival (OS) and progression-free survival (PFS) rates according to FIGO 2009 and FIGO 2018 staging systems were compared using the log-rank test. Cox regression model was used to identify independent prognostic factors for survival. RESULTS The median follow-up was 59 months. Five-year OS and PFS rates were 81.1% and 77.7%, respectively. Stage migration was recorded in 401 patients (70.2%) and the most remarkable stage migration was detected in stage I patients (60%). A total of 157 (27.5%) patients upstaged to stage IIIC disease. According to FIGO 2009, 5-year OS rates were 87.3%, 80.5% (p=0.076), and PFS rates were 82.8%, 77.5% (p=0.036) for stage IB1 and IB2, respectively. According to FIGO 2018, the 5-year OS rates for stage IB1, IB2, and IB3 were 89.8%, 87.1%, and 81.4% (p=0.310), and PFS rates were 90.2%, 80.5%, and 80.1% (p=0.189), respectively. Patients with >= 2 pelvic lymph node (LN) metastases had worse 5-year OS and PFS rates than patients with one metastasis (p=0.015 and p=0.006). Number of para-aortic LN metastasis and metastatic LN ratio (MLNR) were also correlated with 5-year OS and PFS. CONCLUSION Current FIGO staging system better discriminates patients with cervical cancer. However, integration of metastatic LN number and/or MLNR to the upcoming FIGO staging system may improve the prognostic value of the staging.